ArticleJournal of pharmacokinetics and pharmacodynamics2026
Tracer kinetic modeling of a 14 kDa anti-CD8 PET tracer (2C8v144) for in vivo estimation of CD8 expression in tissue and blood, binding affinity, and total body receptor occupancy.
Article in Journal of pharmacokinetics and pharmacodynamics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Monitoring Fetal Somatic Cell Genome EditingHuman gene therapy · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
We are developing a 14.3 kDa anti-CD8 VHH tracer, [[Formula: see text]F]-2C8v144 (binding tracer, B), along with a nonbinding control tracer, [[Formula: see text]F]-2C8v145 (C), in order to track CD8+ (“cytotoxic”) T cells in malignant tumors during immunotherapy by Positron Emission Tomography (PET). Arterial blood concentrations of C and B were monitored in three rhesus monkeys upon i.v. injection of mass doses/kg varying approximately 5–fold for both tracers. Plasma concentrations, calculated from individual hematocrit measurements assuming no cellular uptake, were analyzed by mixed–effects compartmental modeling, by assuming the parameters of non-specific distribution and elimination (estimated based on the PET-based arterial blood concentrations) to be the same for B as for C. C exhibited linear three–compartment kinetics with a mean residence time of 26 min. Nonlinear kinetics of B suggesting saturable, reversible binding outside of circulating blood were described by an average association rate constant, [Formula: see text], and an equilibrium dissociation constant, [Formula: see text]. Binding in blood to circulating CD8+ cells was described by a different association rate constant, [Formula: see text], and the same [Formula: see text]. The total body content of CD8 receptors was estimated at 1.7 nmol/kg body weight, with 2.7% of the total present in blood. The estimate of [Formula: see text], 0.0097/(min·nM), was > 50–fold lower than [Formula: see text] determined in vitro by Surface Plasmon Resonance (SPR, 0.50/(min·nM), yet the estimated [Formula: see text], 0.23 nM, was similar to the SPR estimate (0.13 nM) suggesting that the model informs about affinity. The model also yields predicted total body receptor occupancies and plasma concentrations of unbound B, i.e. the arterial input function needed for analyzing tracer kinetics in malignant tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.